Use of technology when assessing adherence to diabetes self-management behaviors

Current Diabetes Reports

Volumn 14, Issue 9, 2014, Pages

  Driscoll, Kimberly A ^a   Young Hyman, Deborah ^b  

^a FLORIDA STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Blood glucose monitors; Continuous glucose monitors; Diabetes; Diabetes self management behaviors; Health literacy; Insulin pens; Insulin pumps; Medical nutrition therapy; Patient adherence; Physical activity; Provider adherence; Technology

Indexed keywords

GLUCOSE; INSULIN; METFORMIN; NEUTRAL INSULIN;

BLOOD GLUCOSE METER; CLINICAL PRACTICE; DIABETES MELLITUS; DIET THERAPY; GLUCOSE BLOOD LEVEL; HEALTH CARE MANAGEMENT; HUMAN; INSULIN PUMP; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COMPLIANCE; PHYSICAL ACTIVITY; REVIEW; SOCIAL PSYCHOLOGY; BLOOD; BLOOD GLUCOSE MONITORING; HEALTH BEHAVIOR; MEDICAL TECHNOLOGY; PROCEDURES; SELF CARE;

BIOMEDICAL TECHNOLOGY; BLOOD GLUCOSE SELF-MONITORING; DIABETES MELLITUS; HEALTH BEHAVIOR; HUMANS; PATIENT COMPLIANCE; SELF CARE;

EID: 84905666903     PISSN: 15344827     EISSN: 15390829     Source Type: Journal    
DOI: 10.1007/s11892-014-0521-1     Document Type: Review

References (99)

1. Clarke SF, Foster JR. A history of blood glucose meters and their role in self-monitoring of diabetes mellitus. Br J Biomed Sci. 2012;69:83-93.
2. Hood KK, Peterson CM, Rohan JM, Drotar D. Association between adherence and glycemic control in pediatric type 1 diabetes: a meta-analysis. Pediatrics. 2009;124:e1171-9.
3. Heaton PC, Tundia NL, Luder HR. U.S. emergency departments visits resulting from poor medication adherence: 2005-07. J Am Pharm Assoc. 2013;53:513-9.
4. •• Gonzalez JS, Schneider HE. Methodological issues in the assessment of diabetes treatment adherence. Curr Diab Rep. 2011;11:472-9. This article provides a recent overview of medication adherence in type 1 diabetes and highlights the associated measurement issues.
5. •• Laffel L. Psychosocial considerations regarding adoption of intensive management. Psychosocial care for people with diabetes. Alexandria: American Diabetes Association; 2012. This chapter provides an overview of the current literature on the psychosocial benefits and potential barriers to blood glucose monitoring, continuous glucose monitoring, and insulin pens.
6. •• Johnson SB. Adherence to medical regimens. psychosocial care for people with diabetes. Alexandria: American Diabetes Association; 2012. This chapter provides an overview of medical treatment regimen adherence, the relation between adherence and glycemic control, assessing patient and provider adherence, and strategies to improve patient and provider adherence.
7. •• Drotar D. Strategies of adherence promotion in the management of pediatric chronic conditions. J Dev Behav Pediatr. 2013;34:716-29. This article proposes a comprehensive approach to improving adherence by describing a core approach to adherence promotion implemented by pediatric health care providers) follow-up and ongoing management; and tailoring and targeting specific more intensive family-centered interventions to children and adolescents who demonstrate clinically significant treatment nonadherence or risk for nonadherence.
8. Pulgaron ER, Sanders LM, Patino-Fernandez AM, Wile D, Sanchez J, Rothman RL, et al. Glycemic control in young children with diabetes: the role of parental health literacy. Patient Educ Couns. 2014;94:67-70.
9. Scheiner G, Boyer BA. Characteristics of basal insulin requirements by age and gender in Type-1 diabetes patients using insulin pump therapy. Diabetes Res Clin Pract. 2005;69:14-21. (Pubitemid 40813408)
10. DCCT. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med. 1993;329: 977-86.
11. •• Amed S, Nuernberger K, McCrea P, Reimer K, Krueger H, Aydede SK, et al. Adherence to clinical practice guidelines in the management of children, youth, and young adults with type 1 diabetes - a prospective population cohort study. J Pediatr. 2013;163:543-8. This study provides evidence that patients with type 1 diabetes do not adhere to clinical practice guidelines regarding number of visits per year with the diabetes care providers, glucagon prescriptions, and A1C tests performed.
12. McGrady ME, Peugh JL, Hood KK. Illness representations predict adherence in adolescents and young adults with type 1 diabetes. Psychol Health. 2014;29:985-98.
13. Yawn B, Zyzanski SJ, Goodwin MA, Gotler RS, Stange KC. Is diabetes treated as an acute or chronic illness in community family practice? Diabetes Care. 2001;24:1390-6. (Pubitemid 33716426)
14. Kruse RL, Olsberg JE, Oliver DP, Shigaki CL, Vetter-Smith MJ, LeMaster JW. Patient-provider communication about diabetes selfcare activities. Fam Med. 2013;45:319-22.
15. Krane NK, Anderson D, Lazarus CJ, Termini M, Bowdish B, Chauvin S, et al. Physician practice behavior and practice guidelines: using unannounced standardized patients to gather data. J Gen Intern Med. 2009;24:53-6.
16. Siminoff LA, Rogers HL, Waller AC, Harris-Haywood S, Esptein RM, Carrio FB, et al. The advantages and challenges of unannounced standardized patient methodology to assess healthcare communication. Patient Educ Couns. 2011;82:318-24.
17. Driscoll KA, Johnson SB, Hogan J, Gill E, Wright N, Deeb LC. Insulin bolusing software: the potential to optimize health outcomes in type 1 diabetes mellitus. J Diabetes Sci Technol. 2013;7:646-52.
18. Summary of revisions to the 2014 clinical practice recommendations. Diabetes Care. 2014;37(Suppl 1):S4.
19. Stetson B, Schlundt D, Peyrot M, Ciechanowski P, Austin MM, Young-Hyman D, et al. Monitoring in diabetes self-management: issues and recommendations for improvement. PHM. 2011;14: 189-97.
20. Wahowiak L. Blood glucose meters: what to look for and what to know. Diabetes Forecast. 2013;66(1):38-47.
21. •• Miller KM, Beck RW, Bergenstal RM, Goland RS, Haller MJ, McGill JB, et al. Evidence of a strong association between frequency of self-monitoring of blood glucose and hemoglobin A1c levels in T1D exchange clinic registry participants. Diabetes Care. 2013;36:2009-14. This study demonstrates that higher BGM frequency is associated with better glycemic control in more than 20, 000 participants with type 1 and type 2 diabetes.
22. Karter AJ, Ackerson LM, Darbinian JA, D'Agostino Jr RB, Ferrara A, Liu J, et al. Self-monitoring of blood glucose levels and glycemic control: the Northern California Kaiser Permanente Diabetes registry. Am J Med. 2001;111:1-9. (Pubitemid 32635255)
23. O'Connell MA, Donath S, Cameron FJ. Poor adherence to integral daily tasks limits the efficacy of CSII in youth. Pediatr Diabetes. 2011;12:556-9.
24. Driscoll KA, Johnson SB, Resmini A, McGinnity K, Deeb LC. White coat adherence in children and adolescents with type 1 diabetes. Diabetes. 2011;60 Suppl 1:A222.
25. Guilfoyle SM, Crimmins NA, Hood KK. Blood glucose monitoring and glycemic control in adolescents with type 1 diabetes: meter downloads vs self-report. Pediatr Diabetes. 2011;12:560-6.
26. Herzer M, Vesco A, Ingerski LM, Dolan LM, Hood KK. Explaining the family conflict-glycemic control link through psychological variables in adolescents with type 1 diabetes. J Behav Med. 2011;34:268-74.
27. Cohen ND, Hong ES, Van Drie C, Balkau B, Shaw J. Long-term metabolic effects of continuous subcutaneous insulin infusion therapy in type 1 diabetes. Diabetes Technol Ther. 2013;15:544-9.
28. Driscoll KA, Johnson SB, Wang Y, Tang Y, Gill EC, Mitchell A, et al. Importance of manually entering blood glucose readings when wireless-compatible meters are not being used with an insulin pump. J Diabetes Sci Technol. 2013;7:898-903.
29. Helgeson VS, Honcharuk E, Becker D, Escobar O, Siminerio L. A focus on blood glucose monitoring: relation to glycemic control and determinants of frequency. Pediatr Diabetes. 2011;12:25-30.
30. Driscoll KA, Johnson SB, Tang Y, Yang F, Deeb LC, Silverstein JH. Does blood glucose monitoring increase prior to clinic visits in children with type 1 diabetes? Diabetes Care. 2011;34:2170-3.
31. Ingerski LM, Anderson BJ, Dolan LM, Hood KK. Blood glucose monitoring and glycemic control in adolescence: contribution of diabetes-specific responsibility and family conflict. J Adolesc Health. 2010;47:191-7.
32. Larson NS, Pinsker JE. The role of continuous glucose monitoring in the care of children with type 1 diabetes. Int J Pediatr Endocrinol. 2013;2013:8.
33. Bergenstal RM, Tamborlane WV, Ahmann A, Buse JB, Dailey G, Davis SN, et al. Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes. N Engl J Med. 2010;363:311-20.
34. Gandrud LM, Xing D, Kollman C, Block JM, Kunselman B, Wilson DM, et al. The Medtronic Minimed Gold continuous glucose monitoring system: an effective means to discover hypo- and hyperglycemia in children under 7 years of age. Diabetes Technol Ther. 2007;9:307-16. (Pubitemid 47340081)
35. Schiaffini R, Ciampalini P, Fierabracci A, Spera S, Borrelli P, Bottazzo GF, et al. The continuous glucose monitoring system (CGMS) in type 1 diabetic children is the way to reduce hypoglycemic risk. Diabetes Metab Res Rev. 2002;18:324-9.
36. Maia FF, Araujo LR. Efficacy of continuous glucose monitoring system (CGMS) to detect postprandial hyperglycemia and unrecognized hypoglycemia in type 1 diabetic patients. Diabetes Res Clin Pract. 2007;75:30-4. (Pubitemid 44856023)
37. Patton SR, Williams LB, Eder SJ, Crawford MJ, Dolan L, Powers SW. Use of continuous glucose monitoring in young children with type 1 diabetes: implications for behavioral research. Pediatr Diabetes. 2011;12:18-24.
38. Bode BW, Battelino T. Continuous glucose monitoring in 2012. Diabetes Technol Ther. 2013;15 Suppl 1:S13-23.
39. Cemeroglu AP, Stone R, Kleis L, Racine MS, Postellon DC, Wood MA. Use of a real-time continuous glucose monitoring system in children and young adults on insulin pump therapy: patients' and caregivers' perception of benefit. Pediatr Diabetes. 2010;11:182-7.
40. Mazze RS, Strock E, Wesley D, Borgman S, Morgan B, Bergenstal R, et al. Characterizing glucose exposure for individuals with normal glucose tolerance using continuous glucose monitoring and ambulatory glucose profile analysis. Diabetes Technol Ther. 2008;10:149-59. (Pubitemid 351677595)
41. Bergenstal RM, Ahmann AJ, Bailey T, Beck RW, Bissen J, Buckingham B, et al. Recommendations for standardizing glucose reporting and analysis to optimize clinical decision making in diabetes: the ambulatory glucose profile (AGP). Diabetes Technol Ther. 2013;15:198-211.
42. Davies MJ, Gagliardino JJ, Gray LJ, Khunti K, Mohan V, Hughes R. Real-world factors affecting adherence to insulin therapy in patients with Type 1 or Type 2 diabetes mellitus: a systematic review. Diabetes Med. 2013;30:512-24.
43. Kheir N, Greer W, Yousif A, Al-Geed H, Okkah RA, Zirie M, et al. The utility of an electronic adherence assessment device in type 2 diabetes mellitus: a pilot study of single medication. Patient Prefer Adherence. 2010;4:247-54.
44. Bogner HR, Morales KH, de Vries HF, Cappola AR. Integrated management of type 2 diabetes mellitus and depression treatment to improve medication adherence: a randomized controlled trial. Ann Fam Med. 2012;10:15-22.
45. White AJ, Kellar I, Prevost AT, Kinmonth AL, Sutton S, Canny M, et al. Adherence to hypoglycaemic medication among people with type 2 diabetes in primary care. Prim Care Diabetes. 2012;6:27-33.
46. Park LG, Howie-Esquivel J, Dracup K. Electronic measurement of medication adherence. West J Nurs Res. 2014
47. Osborn CY, Mayberry LS, Wallston KA, Johnson KB, Elasy TA. Understanding patient portal use: implications for medication management. J Med Internet Res. 2013;15:e133.
48. Olsen BS, Lilleore SK, Korsholm CN, Kracht T. Novopen Echo(R) for the delivery of insulin: a comparison of usability, functionality and preference among pediatric subjects, their parents, and health care professionals. J Diabetes Sci Technol. 2010;4:1468-75.
49. Israel-Bultman H, Hyllested-Winge J, Kolaczynski M, Steindorf J, Garon J. Comparison of preference for NovoPen 4 with previous insulin pen treatments after 12 weeks in adult patients with type 1 and type 2 diabetes: a multicenter observational study. Clin Ther. 2011;33:346-57.
50. Penfornis A. Performance of a new reusable insulin pen. Diabetes Technol Ther. 2011;13:373-9.
51. Seggelke SA, Hawkins RM, Gibbs J, Rasouli N, Low CC, Draznin B. Effect of glargine insulin delivery method (pen-device vs vialsyringe) on glycemic control and patient preferences in patients with type 1 and type 2 diabetes. Endocr Pract. 2014;20(6):536-9.
52. Sommavilla B, Pietranera G. A randomized, open-label, comparative crossover handling trial between two durable pens in patients with type 1 or 2 diabetes mellitus. J Diabetes Sci Technol. 2011;5:1212-21.
53. Klausmann G, Hramiak I, Qvist M, Mikkelsen KH, Guo X. Evaluation of preference for a novel durable insulin pen with memory function among patients with diabetes and health care professionals. Patient Prefer Adherence. 2013;7:285-92.
54. Kreugel G, Keers JC, Kerstens MN, Wolffenbuttel BH. Randomized trial on the influence of the length of two insulin pen needles on glycemic control and patient preference in obese patients with diabetes. Diabetes Technol Ther. 2011;13:737-41.
55. Danne T, Forst T, Deinhard J, Rose L, Moennig E, Haupt A. No effect of insulin pen with memory function on glycemic control in a patient cohort with poorly controlled type 1 diabetes: a randomized open-label study. J Diabetes Sci Technol. 2012;6:1392-7.
56. Hanas R, de Beaufort C, Hoey H, Anderson B. Insulin delivery by injection in children and adolescents with diabetes. Pediatr Diabetes. 2011;12:518-26.
57. Pfutzner A, Bailey T, Campos C, Kahn D, Ambers E, Niemeyer M, et al. Accuracy and preference assessment of prefilled insulin pen vs vial and syringe with diabetes patients, caregivers, and healthcare professionals. Curr Med Res Opin. 2013;29:475-81.
58. Cuddihy RM, Borgman SK. Considerations for diabetes: treatment with insulin pen devices. Am J Therapeut. 2013;20:694-702.
59. Becker S, Kribben A, Meister S, Diamantidis CJ, Unger N, Mitchell A. User profiles of a smartphone application to support drug adherence-experiences from the iNephro project. PLoS One. 2013;8: e78547.
60. Dayer L, Heldenbrand S, Anderson P, Gubbins PO, Martin BC. Smartphone medication adherence apps: potential benefits to patients and providers: response to Aungst. J Am Pharm Assoc. 2013;53:345.
61. Mednick L, Cogen FR, Streisand R. Satisfaction and quality of life in children with type 1 diabetes and their parents following transition to insulin pump therapy. Children's Health Care. 2004;33:169-83. (Pubitemid 39166583)
62. Fox LA, Buckloh LM, Smith SD, Wysocki T, Mauras N. A randomized controlled trial of insulin pump therapy in young children with type 1 diabetes. Diabetes Care. 2005;28:1277-81. (Pubitemid 40756685)
63. Mack-Fogg JE, Orlowski CC, Jospe N. Continuous subcutaneous insulin infusion in toddlers and children with type 1 diabetes mellitus is safe and effective. Pediatr Diabetes. 2005;6:17-21. (Pubitemid 40514887)
64. Pickup J, Keen H. Continuous subcutaneous insulin infusion at 25 years: evidence base for the expanding use of insulin pump therapy in type 1 diabetes. Diabetes Care. 2002;25:593-8.
65. Plotnick LP, Clark LM, Brancati FL, Erlinger T. Safety and effectiveness of insulin pump therapy in children and adolescents with type 1 diabetes. Diabetes Care. 2003;26:1142-6. (Pubitemid 36929262)
66. Wood JR, Moreland EC, Volkening LK, Svoren BM, Butler DA, Laffel LM. Durability of insulin pump use in pediatric patients with type 1 diabetes. Diabetes Care. 2006;29:2355-60. (Pubitemid 44912235)
67. Maahs DM, Horton LA, Chase HP. The use of insulin pumps in youth with type 1 diabetes. Diabetes Technol Ther. 2010;12 Suppl 1:S59-65.
68. Phillip M, Battelino T, Rodriguez H, Danne T, Kaufman F. Use of insulin pump therapy in the pediatric age-group: consensus statement from the European Society for Paediatric Endocrinology, the Lawson Wilkins Pediatric Endocrine Society, and the International Society for Pediatric and Adolescent Diabetes, endorsed by the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2007;30:1653-62. (Pubitemid 46871195)
69. Tamborlane WV, Fredrickson LP, Ahern JH. Insulin pump therapy in childhood diabetes mellitus: guidelines for use. Treat Endocrinol. 2003;2:11-21. (Pubitemid 37051599)
70. Hilliard ME, Goeke-Morey M, Cogen FR, Henderson C, Streisand R. Predictors of diabetes-related quality of life after transitioning to the insulin pump. J Pediatr Psychol. 2009;34:137-46.
71. Juliusson PB, Graue M, Wentzel-Larsen T, Sovik O. The impact of continuous subcutaneous insulin infusion on health-related quality of life in children and adolescents with type 1 diabetes. Acta Paediatr. 2006;95:1481-7. (Pubitemid 44643566)
72. Valenzuela JM, Patino AM, McCullough J, Ring C, Sanchez J, Eidson M, et al. Insulin pump therapy and health-related quality of life in children and adolescents with type 1 diabetes. J Pediatr Psychol. 2006;31:650-60. (Pubitemid 43999590)
73. Nabhan ZM, Rardin L, Meier J, Eugster EA, Dimeglio LA. Predictors of glycemic control on insulin pump therapy in children and adolescents with type I diabetes. Diabetes Res Clin Pract. 2006;74:217-21. (Pubitemid 44572550)
74. Weissberg-Benchell J, Antisdel-Lomaglio J, Seshadri R. Insulin pump therapy: a meta-analysis. Diabetes Care. 2003;26:1079-87. (Pubitemid 36929252)
75. Burdick J, Chase HP, Slover RH, Knievel K, Scrimgeour L, Maniatis AK, et al. Missed insulin meal boluses and elevated hemoglobin A1c levels in children receiving insulin pump therapy. Pediatrics. 2004;113:e221-4.
76. Pankowska E, Skorka A, Szypowska A, Lipka M. Memory of insulin pumps and their record as a source of information about insulin therapy in children and adolescents with type 1 diabetes. Diabetes Technol Ther. 2005;7:308-14. (Pubitemid 40586375)
77. Olinder AL, Kernell A, Smide B. Missed bolus doses: devastating for metabolic control in CSII-treated adolescents with type 1 diabetes. Pediatr Diabetes. 2009;10:142-8.
78. Vanderwel BW, Messer LH, Horton LA, McNair B, Cobry EC, McFann KK, et al. Missed insulin boluses for snacks in youth with type 1 diabetes. Diabetes Care. 2010;33:507-8.
79. Patton SR, Midyett LK, Dolan LM, Powers SW. A comparison of average daily risk range scores for young children with type 1 diabetes mellitus using continuous glucose monitoring and self-monitoring data. Diabetes Technol Ther. 2012;14:239-43.
80. O'Loughlin G, Cullen SJ, McGoldrick A, O'Connor S, Blain R, O'Malley S, et al. Using a wearable camera to increase the accuracy of dietary analysis. Am J Prev Med. 2013;44:297-301.
81. Patton SR, Dolan LM, Powers SW. Mealtime interactions relate to dietary adherence and glycemic control in young children with type 1 diabetes. Diabetes Care. 2006;29:1002-6. (Pubitemid 44115235)
82. Patton SR, Piazza-Waggoner C, Modi AC, Dolan LM, Powers SW. Family functioning at meals relates to adherence in young children with type 1 diabetes. J Pediatr Child Health. 2009;45:736-41.
83. Patton SR, Dolan LM, Smith LB, Brown MB, Powers SW. Examining mealtime behaviors in families of young children with type 1 diabetes on intensive insulin therapy. Eat Behav. 2013;14:464-7.
84. Smith A. Smartphone Ownership 2013. Pew Research Center, (http://www.pewinternet.org/2013/06/05/smartphone-ownership-2013/). 2013. Accessed 11 April 2014.
85. Karstoft K, Winding K, Knudsen SH, Nielsen JS, Thomsen C, Pedersen BK, et al. The effects of free-living interval-walking training on glycemic control, body composition, and physical fitness in type 2 diabetic patients: a randomized, controlled trial. Diabetes Care. 2013;36:228-36.
86. Zhao G, Ford ES, Li C, Balluz LS. Physical activity in U.S. older adults with diabetes mellitus: prevalence and correlates of meeting physical activity recommendations. J Am Geriatr Soc. 2011;59:132-7.
87. Sundberg F, Forsander G, Fasth A, Ekelund U. Children younger than 7 years with type 1 diabetes are less physically active than healthy controls. Acta Paediatr. 2012;101:1164-9.
88. Trigona B, Aggoun Y, Maggio A, Martin XE, Marchand LM, Beghetti M, et al. Preclinical noninvasivemarkers of atherosclerosis in children and adolescents with type 1 diabetes are influenced by physical activity. J Pediatr. 2010;157:533-9.
89. Marrero DG, Trief PM. Lifestyle modification: exercise. psychosocial care for people with diabetes. Alexandria: American Diabetes Association; 2012.
90. Cichosz SL, Fleischer J, Hoeyem P, Laugesen E, Poulsen PL, Christiansen JS, et al. Objective measurements of activity patterns in people with newly diagnosed Type 2 diabetes demonstrate a sedentary lifestyle. Diabetes Med. 2013;30:1063-6.
91. Andre D, Wolf DL. Recent advances in free-living physical activity monitoring: a review. J Diabetes Sci Technol. 2007;1:760-7.
92. Plasqui G, Bonomi AG, Westerterp KR. Daily physical activity assessment with accelerometers: new insights and validation studies. Obes Rev. 2013;14:451-62.
93. Freedson P, Pober D, Janz KF. Calibration of accelerometer output for children. Med Sci Sports Exerc. 2005;37:S523-30. (Pubitemid 41691815)
94. Corder K, Brage S, Ekelund U. Accelerometers and pedometers: methodology and clinical application. Curr Opin Clin Nutr Metab Care. 2007;10:597-603. (Pubitemid 47254721)
95. Otto AD, Garcia DO, Jakicic JM. Lifestyle intervention strategies to prevent and control type 2 diabetes. Curr Diab Rep. 2008;8:407-12.
96. Rathleff MS, Bandholm T, Ahrendt P, Olesen JL, Thorborg K. Novel stretch-sensor technology allows quantification of adherence and quality of home-exercises: a validation study. Br J Sports Med. 2014;48:724-8.
97. Breton ER, Fuemmeler BF, Abroms LC.Weight loss-there is an app for that! But does it adhere to evidence-informed practices? Transl Behav Med. 2011;1:523-9.
98. Pagoto S, Schneider K, Jojic M, DeBiasse M, Mann D. Evidence-based strategies in weight-loss mobile apps. Am J Prev Med. 2013;45:576-82.
99. Miller GD, Jakicic JM, Rejeski WJ, Whit-Glover MC, Lang W, Walkup MP, et al. Effect of varying accelerometry criteria on physical activity: the look ahead study. Obesity. 2013;21:32-44.